logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
C

Chunxia Su

tongji university
H指数:45
被引数:7,293

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer

EGFR突变型早期可切除非小细胞肺癌中分子残留病灶检测的临床应用

Nature Communications
IF15.7
2026-08-100
OA
Fei Zhou; Chunxia Su; Wenhua Liang; Li-Di Xu; Wei Tao; Juanjuan Qian; Shidong Xu; Dan Liu; Rui Fan; Yaxi Zhang; Yiqian Liu; Lin Wu; Xiangning Fu; Xiaodong Zhang; Ning Shen; Di Ge; Qun Chen; Weimin Mao; Lin Xu; Chun Chen; Bing Hu; Guoguang Shao; Jian Hu; Jian Zhao; Xiaoqing Liu; Zhidong Liu; Zheng Wang; Zemin Xiao; Taiqian Gong; Wen Lin; Xingya Li; Feng Ye; Yang Liu; Haitao Ma; Yunchao Huang; Jianying Zhou; Zhonglin Wang; Junke Fu; Lieming Ding; Li Mao; Weizhi Chen; Jianxing He; Caicun Zhou
Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial

卡度尼利单抗联合化疗作为PD-L1阴性晚期非小细胞肺癌的一线治疗：一项II期临床试验

Nature Communications
IF15.7
2026-06-120
OAAI
Li Wang; Chuangzhou Rao; Qi Wang; Kuofang Huang; Li Liu; Jing Zhao; Yan Wu; Jianing Chen; Jialin Qian; Haijiao Lu; Shifei Pan; Liangqin Nie; Haoran Tang; Hang Dong; Shi-Dong Jia; Yichao Zang; Tianqing Chu; Chunxia Su
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study

利用局部和系统性免疫特征分析，区分广泛期小细胞肺癌中接受一线信迪利单抗（anti-PD-1抗体）联合化疗的不同应答者：一项Ⅱ期研究的探索性生物标志物分析

SIGNAL TRANSDUCTION AND TARGETED THERAPY
IF52.7
2025-05-230
OA
Xie, Mengqing; Bao, Minwei; Dong, Xiaorong; Wu, Lin; Liu, Li; Zhao, Jing; Chu, Xiangling; Wu, Yan; Ji, Xianxiu; Fang, Yujia; Yu, Xin; Zhang, Shiji; Wang, Qi; Hu, Tao; Wang, Jin; Zhu, Changbin; Su, Chunxia
Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts

骨转移通过产生骨桥蛋白的破骨细胞，削弱了针对检查点阻断免疫疗法的骨外反应。

Cancer Cell
IF44.5
2025-04-240
PRE
Jia-Nan Cheng; Zheng Jin; Chunxia Su; Tao Jiang; Xiaobin Zheng; Jinming Guo; Xingyi Li; Han Chu; Jia Jia; Qin Zhou; Xiaofang Ding; Yiwen Zhang; Shouxia Xu; Fancong Dong; Qiao Zhang; Xinxin Yang; Tao Yang; Xiaoming Cheng; Haoran Zha; Degao Chen; Yisong Y. Wan; Xindong Liu; Lilin Ye; Haidong Tang; Alistair L.J. Symonds; Qi-Jing Li; Qingzhu Jia; Bo Zhu

研究方向

暂未获取到该数据
任胜祥 封面图
任胜祥
H 指数:59论文数:390被引数:1.6万
李雪飞 封面图
李雪飞
H 指数:49论文数:253被引数:8,498
T
Tao Jiang
H 指数:49论文数:363被引数:8,685
C
Chao Zhao
H 指数:38论文数:187被引数:4,992
F
Fei Zhou
H 指数:38论文数:172被引数:5,662
G
Guanghui Gao
H 指数:37论文数:149被引数:4,431
X
Xiaoxia Chen
H 指数:39论文数:313被引数:5,691
C
Caicun Zhou
H 指数:42论文数:229被引数:7,857
F
Fengying Wu
H 指数:29论文数:171被引数:4,184
C
Caicun Zhou
H 指数:49论文数:390被引数:1.1万